MP14-19 SALVAGE IMMUNE CHECKPOINT INHIBITOR (IO) PLUS TYROSINE KINASE INHIBITOR (TKI) COMBINATION THERAPY FOR METASTATIC RENAL CELL CARCINOMA (mRCC)

INTRODUCTION AND OBJECTIVE:IO/TKI combinations are a new standard of care for the initial treatment (tx) of mRCC. Efficacy and toxicity of such combination regimens beyond the first-line (1L) setti...